Managing Advanced Stages of Friedreich’s Ataxia: Challenges and Emerging Therapeutic Avenues

A health care provider outlines treatment objectives and supportive interventions for managing Friedreich ataxia, addressing associated comorbidities and symptoms in clinical settings.

A key opinion leader examines the November 2022 guidelines for managing Friedreich's ataxia, discusses the first FDA-approved therapy for the condition, and explains how this treatment is integrated into current disease management strategies.

An expert in Friedreich's ataxia evaluates the mFARS (modified Friedreich's Ataxia Rating Scale) measurement tool, highlighting its advantages and limitations, while also exploring alternative assessment methods for tracking disease progression.

A key opinion leader outlines common adverse events associated with omaveloxolone treatment in Friedreich's ataxia patients and describes strategies used to manage or minimize these adverse effects.

A physician examines clinical trial results that impact their approach to treating patients with Friedreich ataxia.

A key opinion leader explores new and promising treatment approaches for managing advanced stages of Friedreich ataxia.

A Friedreich ataxia specialist shares their optimistic outlook on future developments in the management of the condition.

A Friedreich ataxia specialist discusses how the typical clinical presentation of Friedreich's Ataxia includes early onset with symptoms such as ataxia and sensory loss, while also examining the pathophysiology and incidence rate of the condition.

Panelists discuss how the differential diagnosis for Friedreich's Ataxia involves distinguishing it from other ataxias, the process of definitive diagnosis through genetic testing, and the significant emotional and practical impact that such a diagnosis has on affected families.

Sub Subramony, M.D., discusses how the progression of patients' conditions often leads to a decline in quality of life and functional capabilities, highlighting key clinical indicators that necessitate the adoption of mobility aids.

Sub Subramony, M.D., discusses how the modified Friedreich Ataxia Rating Scale (mFARS) is valuable for monitoring disease progression in clinical trials and its applicability in everyday clinical practice for assessing patient status.

Sub Subramony, M.D., discusses the most prevalent complications and comorbidities in Friedreich ataxia, emphasizing the frequent cardiac complications and their significant impact on mortality rates.

Sub Subramony, M.D., discusses the challenges faced by patients with Friedreich ataxia in accessing healthcare services and managing their condition, as well as the significant burden the disease places on families and caregivers.

Sub Subramony, M.D., discusses strategies to enhance support for patients with Friedreich ataxia in clinical settings and the broader community, along with his aspirations for future research aimed at addressing unmet needs in treatment and patient support.